Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38650561 | 1.00 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL25985418 | 1.00 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL22997280 | 1.00 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL10073751 | 0.96 | TDP1 (0.53) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL30917974 | 0.93 | TDP1 (0.51) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL12885084 | 0.93 | TDP1 (0.56) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL22276641 | 0.93 | TDP1 (0.56) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL22276648 | 0.93 | TDP1 (0.56) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL13055393 | 0.91 | TDP1 (0.58) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL18591853 | 0.89 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-14 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| CN-116806159-A | Immunoconjugates comprising kallikrein-related peptidase 2 antigen binding domains and uses thereof | 詹森生物科技公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116615194-A | Macrocyclic compounds and methods of use thereof | 詹森生物科技公司 | 2023-08-18 | — | — | CN | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2022270987-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | (주) 업테라 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022235699-A2 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018119357-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20160287713-A1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-10-06 | — | — | US | disclosed |
| US-20160022642-A1 | Compounds Useful for Promoting Protein Degradation and Methods Using Same | YALE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| US-20160022642-A1 | Compounds Useful for Promoting Protein Degradation and Methods Using Same | YALE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| WO-2015075699-A1 | DOTAM DERIVATIVES FOR THERAPEUTIC USE | SANOFI (FR) | 2015-05-28 | — | — | WO | disclosed |
| US-20150119435-A1 | COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME | YALE UNIVERSITY | 2015-04-30 | — | — | US | disclosed |
| US-20140235861-A1 | METHOD FOR THE SYNTHESIS OF 18F-LABELLED BIOMOLECULES | GE HEALTHCARE LIMITED (GB) | 2014-08-21 | — | — | US | disclosed |
| EP-1814879-B1 | DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME | SOD CONSEILS RECH APPLIC (FR) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MEN1 4055/4885KMT2A 445/4885 |
| US-20150119435-A1 | COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME | PSMG3, ERAP1, SMURF2 | TDP1 2697/4885MEN1 4053/4885KMT2A 2256/4885 |
| US-20140235861-A1 | METHOD FOR THE SYNTHESIS OF 18F-LABELLED BIOMOLECULES | GMPS, PAICS, APOBEC3C | TDP1 675/4885MEN1 799/4885KMT2A 2491/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MEN1 4055/4885KMT2A 445/4885 |
| US-20160022642-A1 | Compounds Useful for Promoting Protein Degradation and Methods Using Same | AR, SHBG, PSMG3 | TDP1 3092/4885MEN1 3708/4885KMT2A 2647/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MEN1 4055/4885KMT2A 445/4885 |
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | CGAS, SSB, FPGS | TDP1 45/4885MEN1 2128/4885KMT2A 2247/4885 |
| US-20160287713-A1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | HDGF, TTPA, ELANE | TDP1 1432/4885MEN1 592/4885KMT2A 2981/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MEN1 4055/4885KMT2A 445/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MEN1 4055/4885KMT2A 445/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MEN1 4055/4885KMT2A 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.